Bristol-Myers Squibb Valuation
Is BMY * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BMY * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BMY * (MX$773.49) is trading below our estimate of fair value (MX$1777.84)
Significantly Below Fair Value: BMY * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BMY *?
Other financial metrics that can be useful for relative valuation.
What is BMY *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$90.63b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3x |
Enterprise Value/EBITDA | 7.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BMY *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.9x | ||
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$15.8b |
GSK GSK | 2.4x | 4.7% | UK£73.8b |
ZTS Zoetis | 9.1x | 6.0% | US$77.1b |
MRK Merck KGaA | 3.3x | 4.3% | €68.8b |
BMY * Bristol-Myers Squibb | 2x | -1.6% | Mex$90.6b |
Price-To-Sales vs Peers: BMY * is good value based on its Price-To-Sales Ratio (2x) compared to the peer average (3.9x).
Price to Earnings Ratio vs Industry
How does BMY *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Sales vs Industry: BMY * is good value based on its Price-To-Sales Ratio (2x) compared to the Global Pharmaceuticals industry average (2.5x).
Price to Sales Ratio vs Fair Ratio
What is BMY *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BMY *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$773.49 | Mex$894.31 +15.6% | 16.7% | Mex$1,260.91 | Mex$622.05 | n/a | 22 |
May ’25 | Mex$758.75 | Mex$911.18 +20.1% | 15.8% | Mex$1,276.34 | Mex$629.66 | n/a | 23 |
Apr ’25 | Mex$885.00 | Mex$936.11 +5.8% | 13.3% | Mex$1,242.63 | Mex$679.30 | n/a | 23 |
Mar ’25 | Mex$860.00 | Mex$967.75 +12.5% | 15.8% | Mex$1,450.66 | Mex$699.73 | n/a | 22 |
Feb ’25 | Mex$825.50 | Mex$1,040.38 +26.0% | 16.7% | Mex$1,457.82 | Mex$720.33 | n/a | 23 |
Jan ’25 | Mex$867.51 | Mex$1,051.57 +21.2% | 16.5% | Mex$1,443.50 | Mex$713.26 | n/a | 23 |
Dec ’24 | Mex$852.00 | Mex$1,097.18 +28.8% | 17.0% | Mex$1,539.70 | Mex$855.39 | n/a | 24 |
Nov ’24 | Mex$921.36 | Mex$1,168.56 +26.8% | 16.0% | Mex$1,603.11 | Mex$890.62 | n/a | 23 |
Oct ’24 | Mex$1,012.00 | Mex$1,241.20 +22.6% | 13.0% | Mex$1,541.35 | Mex$941.94 | n/a | 23 |
Sep ’24 | Mex$1,050.00 | Mex$1,241.72 +18.3% | 13.4% | Mex$1,534.48 | Mex$954.79 | n/a | 24 |
Aug ’24 | Mex$1,034.03 | Mex$1,225.83 +18.5% | 13.6% | Mex$1,540.48 | Mex$937.69 | n/a | 24 |
Jul ’24 | Mex$1,090.12 | Mex$1,342.83 +23.2% | 12.4% | Mex$1,571.04 | Mex$1,007.51 | n/a | 22 |
Jun ’24 | Mex$1,116.00 | Mex$1,408.26 +26.2% | 12.4% | Mex$1,639.02 | Mex$1,051.11 | n/a | 21 |
May ’24 | Mex$1,200.00 | Mex$1,411.66 +17.6% | 11.8% | Mex$1,649.43 | Mex$1,057.79 | Mex$758.75 | 21 |
Apr ’24 | Mex$1,236.22 | Mex$1,447.84 +17.1% | 11.4% | Mex$1,719.41 | Mex$1,122.14 | Mex$885.00 | 21 |
Mar ’24 | Mex$1,272.00 | Mex$1,545.37 +21.5% | 10.9% | Mex$1,802.06 | Mex$1,176.08 | Mex$860.00 | 19 |
Feb ’24 | Mex$1,327.69 | Mex$1,527.07 +15.0% | 11.0% | Mex$1,788.80 | Mex$1,129.77 | Mex$825.50 | 19 |
Jan ’24 | Mex$1,408.25 | Mex$1,576.21 +11.9% | 10.9% | Mex$1,818.74 | Mex$1,186.13 | Mex$867.51 | 19 |
Dec ’23 | Mex$1,551.00 | Mex$1,538.69 -0.8% | 10.4% | Mex$1,747.23 | Mex$1,164.82 | Mex$852.00 | 19 |
Nov ’23 | Mex$1,518.00 | Mex$1,571.63 +3.5% | 10.6% | Mex$1,785.45 | Mex$1,190.30 | Mex$921.36 | 18 |
Oct ’23 | Mex$1,439.30 | Mex$1,599.69 +11.1% | 10.6% | Mex$1,872.25 | Mex$1,214.97 | Mex$1,012.00 | 19 |
Sep ’23 | Mex$1,388.21 | Mex$1,606.31 +15.7% | 10.0% | Mex$1,837.58 | Mex$1,218.40 | Mex$1,050.00 | 19 |
Aug ’23 | Mex$1,500.00 | Mex$1,638.13 +9.2% | 10.0% | Mex$1,875.34 | Mex$1,243.43 | Mex$1,034.03 | 19 |
Jul ’23 | Mex$1,547.00 | Mex$1,583.48 +2.4% | 10.1% | Mex$1,842.94 | Mex$1,262.02 | Mex$1,090.12 | 19 |
Jun ’23 | Mex$1,472.00 | Mex$1,544.63 +4.9% | 10.3% | Mex$1,842.47 | Mex$1,234.84 | Mex$1,116.00 | 21 |
May ’23 | Mex$1,540.00 | Mex$1,570.01 +1.9% | 9.8% | Mex$1,918.42 | Mex$1,306.16 | Mex$1,200.00 | 21 |
Analyst Forecast: Target price is less than 20% higher than the current share price.